Systemic SP-A is increased in COVID-19 patients with abnormal diffusion capacity 6 months after hospital discharge
O. Sibila Vidal (Barcelona, Spain), N. Albacar (Barcelona, Spain), L. Perea (Barcelona, Spain), T. Garcia (Barcelona, Spain), N. Mendoza (Barcelona, Spain), T. Cruz (Barcelona, Spain), S. Casas (Barcelona, Spain), J. Moisés (Barcelona, Spain), J. Badia (Barcelona, Spain), J. Barberà (Barcelona, Spain), A. Agustí (Barcelona, Spain), J. Sellarés (Barcelona, Spain), R. Faner (Barcelona, Spain), L. Perea Soriano (Barcelona (CT), Spain)
Source: Virtual Congress 2021 – Chronic COVID - 19
Session: Chronic COVID - 19
Session type: Oral Presentation
Number: 85
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Sibila Vidal (Barcelona, Spain), N. Albacar (Barcelona, Spain), L. Perea (Barcelona, Spain), T. Garcia (Barcelona, Spain), N. Mendoza (Barcelona, Spain), T. Cruz (Barcelona, Spain), S. Casas (Barcelona, Spain), J. Moisés (Barcelona, Spain), J. Badia (Barcelona, Spain), J. Barberà (Barcelona, Spain), A. Agustí (Barcelona, Spain), J. Sellarés (Barcelona, Spain), R. Faner (Barcelona, Spain), L. Perea Soriano (Barcelona (CT), Spain). Systemic SP-A is increased in COVID-19 patients with abnormal diffusion capacity 6 months after hospital discharge. 85
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: